Patent · US Active

Anti-EGFR antibodies

US7723484B2 · kind B2 · utility

49Cited by

0References

4Claims

0Family size

Assignee

Applied Molecular Evolution, Inc. · US

Inventors

Catherine Brautigam Beidler · Poway, US
Alain P. Vasserot · South San Francisco, US
Jeffry D. Watkins · Encinitas, US

Key dates

Filing date	Nov 6, 2006
Grant date	May 25, 2010
Priority date	—
Expiry date	Apr 12, 2027

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention encompasses EGFR specific monoclonal antibodies, or antigen-binding portions thereof. These antibodies, or antigen-binding portions thereof, have high affinity for EGFR, inhibit the activation of EGFR, and are useful for the treatment of EGFR mediated cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.